Hsp90 inhibitors in breast cancer: A systematic review

被引：59

作者：

Zagouri, Flora ^{[1
]}

Sergentanis, Theodoros N. ^{[1
]}

Chrysikos, Dimosthenis ^{[2
]}

Papadimitriou, Christos A. ^{[1
]}

Dimopoulos, Meletios-Athanassios ^{[1
]}

Psaltopoulou, Theodora ^{[3
]}

机构：

[1] Univ Athens, Sch Med, Alexandra Hosp, Dept Clin Therapeut, Athens 11521, Greece

[2] Univ Athens, Sch Med, Hippocrateio Hosp, Propaedeut Surg Dept 1, Athens 11521, Greece

[3] Univ Athens, Sch Med, Dept Hyg Epidemiol & Med Stat, Athens 11521, Greece

来源：

BREAST | 2013年 / 22卷 / 05期

关键词：

Breast cancer; Hsp90; inhibitors; Tanespimycin; Alvespimycin; Retaspimycin; HEAT-SHOCK-PROTEIN; PHASE-I TRIAL; TANESPIMYCIN; 17-AAG; ANTITUMOR EFFICACY; DOSE-ESCALATION; 17-ALLYLAMINO-17-DEMETHOXYGELDANAMYCIN; HEAT-SHOCK-PROTEIN-90; TRASTUZUMAB; HYDROCHLORIDE; COMBINATION;

D O I：

10.1016/j.breast.2013.06.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: Pharmacological inhibition of Hsp90 shows great promise in breast cancer treatment. This is the first systematic review to synthesize all available data and to evaluate the efficacy and safety of Hsp90 inhibitors in breast cancer. Methods: This study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by a search of MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms "breast", "cancer", "Hsp90", "inhibitors". Results: Overall, 19 articles (190 patients) were eligible. The greatest clinical activity has been observed on the field of HER2-positive metastatic breast cancer. However, accumulating data suggest that Hsp90 inhibitors may play a significant role in the treatment of triple negative and aromatase inhibitor-resistant breast cancer. Conclusion: In the last decade, the development of Hsp90 inhibitors has moved forward rapidly; however, no phase III trials have been conducted and none agent has been approved for use in the clinical practice. (C) 2013 Elsevier Ltd. All rights reserved.

引用

页码：569 / 578

页数：10

共 50 条

[41] A fluorescence polarization assay for inhibitors of Hsp90 [J].

Howes, R ;

Barril, X ;

Dymock, BW ;

Grant, K ;

Northfield, CJ ;

Robertson, AGS ;

Surgenor, A ;

Wayne, J ;

Wright, L ;

James, K ;

Matthews, T ;

Cheung, KM ;

McDonald, E ;

Workman, P ;

Drysdale, MJ .

ANALYTICAL BIOCHEMISTRY, 2006, 350 (02) :202-213

[42] Maximizing the Therapeutic Potential of HSP90 Inhibitors [J].

Butler, Lisa M. ;

Ferraldeschi, Roberta ;

Armstrong, Heather K. ;

Centenera, Margaret M. ;

Workman, Paul .

MOLECULAR CANCER RESEARCH, 2015, 13 (11) :1445-1451

[43] Inhibition of HSP90 molecular chaperones: moving into the clinic [J].

Garcia-Carbonero, Rocio ;

Carnero, Amancio ;

Paz-Ares, Luis .

LANCET ONCOLOGY, 2013, 14 (09) :E358-E369

[44] Organelle-specific Hsp90 inhibitors [J].

Seo, Young Ho .

ARCHIVES OF PHARMACAL RESEARCH, 2015, 38 (09) :1582-1590

[45] Hsp90 inhibitors as promising agents for radiotherapy [J].

Kabakov, Alexander E. ;

Kudryavtsev, Vladimir A. ;

Gabai, Vladimir L. .

JOURNAL OF MOLECULAR MEDICINE-JMM, 2010, 88 (03) :241-247

[46] Targeting the molecular chaperone heat shock protein 90 (HSP90): Lessons learned and future directions [J].

Hong, David S. ;

Banerji, Udai ;

Tavana, Bahareh ;

George, Goldy C. ;

Aaron, Joann ;

Kurzrock, Razelle .

CANCER TREATMENT REVIEWS, 2013, 39 (04) :375-387

[47] Inhibition of heat shock protein (Hsp) 27 potentiates the suppressive effect of Hsp90 inhibitors in targeting breast cancer stem-like cells [J].

Lee, Che-Hsin ;

Hong, Hui-Mei ;

Chang, Yu-Ying ;

Chang, Wen-Wei .

BIOCHIMIE, 2012, 94 (06) :1382-1389

[48] Hsp90: an emerging target for breast cancer therapy [J].

Beliakoff, J ;

Whitesell, L .

ANTI-CANCER DRUGS, 2004, 15 (07) :651-662

[49] Dual mode of cancer cell destruction for pancreatic cancer therapy using Hsp90 inhibitor loaded polymeric nano magnetic formulation [J].

Rochani, Ankit K. ;

Balasubramanian, Sivakumar ;

Girija, Aswathy Ravindran ;

Raveendran, Sreejith ;

Borah, Ankita ;

Nagaoka, Yutaka ;

Nakajima, Yoshikata ;

Maekawa, Toru ;

Kumar, D. Sakthi .

INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2016, 511 (01) :648-658

[50] HSP90 inhibition: two-pronged exploitation of cancer dependencies [J].

Travers, Jon ;

Sharp, Swee ;

Workman, Paul .

DRUG DISCOVERY TODAY, 2012, 17 (5-6) :242-252

← 1 2 3 4 5 →